Hypereosinophilic Syndromes Patient Conference

APFED’s Hypereosinophilic Syndromes Patient Education and Drug Development Conference was held March 23, 2018, in Rockville, MD. It offered a unique opportunity to learn about treatments and research advances for hypereosinophilic syndromes (HES), and to share perspectives with the FDA and other key stakeholders about the impact HES has had on on people with HES and their families, as well as learn about their views on current treatment approaches. Dynamic sessions and question and answer opportunities allowed all those who participated in-person and by live webcast to learn and share knowledge.

Thank you to our education partner Knopp Biosciences for supporting the conference.


Conference Materials


Patient Perspective Summary Report


Conference Transcripts


Conference Recordings

Conference Opening and Welcome Remarks

Dr. Wendy Book
APFED President


Patient-Centered Therapies: The Role of the Patient in Drug Development (Part 1)

Dr. Calman Prussin
Knopp Biosciences


Patient-Centered Therapies: The Role of the Patient in Drug Development (Part 2)

Dr. Dawn Phillips


Hypereosinophilic Syndromes, Then and Now: Perspective Piece

Dr. Gerald Gleich
University of Utah


Patient Perspectives on Impact of Disease on Daily Life

Patient Panel


Patient Perspectives on Current Therapies

Patient Panel


Current Treatment Options and Side Effects

Dr. Paneez Khoury
National Institutes of Health


Patient Perspectives on Ideal Treatments

Patient Panel


Pediatric vs Adult HES

Dr. Patricia Fulkerson
Cincinnati Children’s Hospital Medical Center


Connecting with Resources and Support: For Patients and Providers

Mary Jo Strobel
APFED Executive Director


Questions? Email conference@apfed.org.